Life Healthcare Group Holdings Limited · JSE:LHC
Life Healthcare — Investor Day (February 2025)
84 slides from Life Healthcare's investor day presentation, Feb 27, 2025
Slide 1: Capital Markets Day: Life Healthcare
Capital Markets Day: Life Healthcare February 2025
Slide 2: Contents
CONTENTS OVERVIEW GROW DRIVE OPTIMISE CONCLUSION LIFE MOLECULAR IMAGING
Slide 3: Our Purpose
Our Purpose Why do we exist? • Our purpose: Making life better How do we achieve our purpose? • Our mission: We improve the lives of people through delivery of high-quality, cost- effective care What do we want to achieve? • Our vision: To be the preferred healthcare provider and the best place to w
Slide 4: Life Healthcare business lines and facilities
16,108 over 3,000 7 learning centres employees specialists in our network 85.7% of turnover 8.6% of turnover Acute Hospitals 42 facilities Life Nkanyisa 8,145 acute hospital beds 282 theatres 2,308 beds 7 facilities 4 provinces 17 cathlabs 9 vascular labs Life Health Solutions A&E Units occupational
Slide 5: Meet the team with over 270 years of experience in healthcare
Meet the team with over 270 years of experience in healthcare Adam Pyle Andre Joseph Asanda Myataza Avanthi Brett Mill Craig Koekemoer David Price Joshila Chief Strategy Funders & Finance Executive Parboosing Chief Actuary Chief Operations Ranchhod Chief Information and Growth Health Policy and Data
Slide 6: Market overview
Market overview We are facing a number of market challenges … SOUTH AFRICA circa 9m Human resource challenges, Consolidated hospital and funder Insured lives across SA, with a lack Increasingly competitive market especially within clinical market in growth resources …Despite these challenges, there
Slide 7: Population and medical aid beneficiaries by age
Population and medical aid beneficiaries by age Life Healthcare Revenue / PPD by Age An ageing insured population 2009 2014 2019 2024 Key Findings PPD %: Patients > 39.7 46.1 50.2 53.8 50 years Rev %: Patients > 46.5 52.8 57.4 61.2 ▪ The % of beneficiaries that are 60+ years has 50 years increased f
Slide 8: Prevalence of chronic diseases has doubled over the last 15 years
Prevalence of chronic diseases has doubled over the last 15 years Chronic diseases amongst beneficiaries (count per 1,000 beneficiaries), 2009, 2014, 2019 and 2023 200 • This graph represents the number of beneficiaries registered on a chronic disease 180 management program • Leading chronic disease
Slide 9: Progression in non-acute growth to increase market access
Progression in non-acute growth to increase market access Revenue by segment 24 000 CAGR 23 000 22 000 21 000 14.0% 20 000 19 000 18 000 17 000 16 000 15 000 2019 2022 2023 2024 Acute Comp Serv HCS Life Healthcare has 3 business lines – Acute, Complementary Services, and HCS Acute Core part of the G
Slide 10: Continuous improvement in asset utilisation
Continuous improvement in asset utilisation Occupancy % - General ward vs ICU Occupancy split by facilities % 8 000 90.0% 2 3 7 000 80.0% 8 8 14 70.0% 19 6 000 5 000 60.0% 35 50.0% 4 000 40.0% 47 3 000 42 30.0% 36 2 000 31 20.0% 55 1 000 10.0% - FY2024 FY2022 FY2023 FY2022 FY2023 FY2024 < 60% 60-69%
Slide 11: Growing disease burden driving increased demand
Growing disease burden driving increased demand Core Focus: Acute and Complementary Services Acute Imaging & Nuclear Acute Rehab Mental Health Renal Dialysis Oncology Medicine Non-communicable Approximately 10% Almost half of the Chronic Kidney PET-CT is Approximately 50% diseases such as of South A
Slide 12: Grow, Drive, Optimise
Grow, Drive, Optimise GROW DRIVE OPTIMISE Grow footprint in strategic Drive facilities utilisation Optimise asset utilisation locations Greenfield expansion by targeting new GP channel Strategically optimise asset builds in growth geographies utilisation A&E unit channel Brownfield expansion of exis
Slide 13: Overview: Questions
OVERVIEW OVERVIEW QUESTIONS
Slide 14: Section 1: Grow
SECTION 1: GROW GROW ACUTE Slides 15-26 HOW? Greenfield expansion RENAL Slides 28-29 Increased Brownfield expansion footprint in strategic locations to ensure broader Acquisitions of new facilities IMAGING Slides 30-38 access Expansion of complementary lines of business ONCOLOGY Slides 39-42
Slide 15: Overview and introduction to our Acute Growth Strategy
ACUTE RENAL IMAGING ONCOLOGY Overview and introduction to our Acute Growth Strategy We are facing a number of market challenges … SOUTH AFRICA 9m 9m circa circa Human resource challenges, Consolidated InsuredInsured lives across lives across SA, SA, with with a lack a lack Increasingly Increasingly
Slide 16: Analyses and stakeholder engagement to inform growth strategy
To inform and guide our growth strategy, we conduct thorough analyses and engage relevant stakeholders Market and economic research including population movements, patient demographics and geographical spread of services Utilise internal data sets and doctor and hospital statistics Detailed funder a
Slide 17: Increasing capacity - aligned to where services are required
ACUTE RENAL IMAGING ONCOLOGY Increasing capacity - aligned to where services are required Increasing capacity Achieved through...Brownfield expansion at existing facilities where demand is high In Progress: In Planning: 105 Acute beds (ICU / GW) 106 Acute beds (ICU / +180 +156 Pretoria 75 MH/AR beds
Slide 18: Greenfield case study: Life Paarl Valley Hospital
ACUTE RENAL IMAGING ONCOLOGY Greenfield case study: Life Paarl Valley Hospital Life Healthcare has a unique opportunity to operate a 140 -bed acute hospital in the Cape Winelands area in partnership T h e L i f e P a a r l Va l l e y H o s p i t a l Key Differentiators license comprises... Bed compo
Slide 19: Greenfield case study: Life Paarl Valley Hospital
ACUTE RENAL IMAGING ONCOLOGY Greenfield case study: Life Paarl Valley Hospital PA A R L A R E A Drakenstein Population 251,262 2011 (Census) MAP VIEW 280,195 2016 (StatsSA) Paarl 350,000 2024 current estimate ▪ Migration is one of the contributors to the population growth ▪ Area is earmarked as a gr
Slide 20: Greenfield case study: Life Paarl Valley finances
ACUTE RENAL IMAGING ONCOLOGY Greenfield case study: Life Paarl Valley L i f e P a a r l Va l l e y H o s p i t a l : F i n a n c e s Total Capitalised Development Costs Total development costs include: Landlord contribution ~R600m Infrastructure costs to allow for future expansion (20-year lease wit
Slide 21: Brownfield expansion example: East Coast Region
ACUTE RENAL IMAGING ONCOLOGY Brownfield expansion example: Coast East Region Within the East Coast region, we have upcoming brownfield projects across KZN, North-West and the Free State KZN NORTH WEST 1. Life Hilton Private Hospital Expansion Life Anncron Hospital UPCOMING PROJECTS UPCOMING PROJECTS
Slide 22: KZN Case Study: Life Hilton Private Hospital
ACUTE RENAL IMAGING ONCOLOGY KZN Case Study: Life Hilton Private Hospital Overview Expansion planned Context 36 Medical ward beds 100 bed hospital which was developed as a greenfield project in 2015 24 Acute rehabilitation beds Current occupancies of 75% with the hospital often on divert 9 High care
Slide 23: KZN Case Study: Life Hilton Private Hospital
ACUTE RENAL IMAGING ONCOLOGY KZN Case Study: Life Hilton Private Hospital Campus Overview New Build – Consulting Rooms • x5 Specialist Consulting Rooms Conversion – Existing space • Med Ward to Oncology (Surgical & Medical) (20 beds) New • ICU/HC mixed to ICU (16 beds) Staff • Day Ward to High Care
Slide 24: KZN Case Study: Life Mount Edgecombe Hospital
ACUTE RENAL IMAGING ONCOLOGY KZN Case Study: Life Mount Edgecombe Hospital Overview Expansion planned Context Life Mount Edgecombe Hospital is a 183-bed community 13 Additional ICU beds hospital in north Durban A cathlab including a radial The hospital offers the full suite of medical disciplines in
Slide 25: North-West Case Study: Life Anncron Hospital
ACUTE RENAL IMAGING ONCOLOGY North-West Case Study: Life Anncron Hospital Overview Expansion planned Context Life Anncron Hospital is a 157 bed hospital located in the 40 Additional acute rehabilitation North West Province and sub-acute beds The hospital includes a cathlab and recently revamped and
Slide 26: Free State Case Study: Life Rosepark Hospital
ACUTE RENAL IMAGING ONCOLOGY Free State Case Study: Life Rosepark Hospital Overview Expansion planned Context Life Rosepark Hospital is a 268-bed hospital in Bloemfontein It is regularly the recipient of the Best Private Hospital in Bloemfontein and Discovery excellence awards, featuring high-tech f
Slide 27: Section 1: Grow
SECTION 1: GROW GROW ACUTE Complete HOW? Greenfield expansion RENAL Slides 28-29 Increased footprint in Brownfield expansion strategic locations to ensure broader IMAGING Slides 30-38 Acquisition of new facilities access Expand complementary lines of business ONCOLOGY Slides 39-42
Slide 28: Increasing demand for renal therapies in South Africa
ACUTE RENAL IMAGING ONCOLOGY Increasing demand for renal therapies in South Africa GREATER DEMAND FOR RENAL THERAPIES IN SOUTH AFRICA … 6 13% 80% R720k million CAGR Estimated prevalence of forecast in the South African of new kidney replacement per patient per year to undergo end-stage renal dialysi
Slide 29: Growing the renal footprint across South Africa
ACUTE RENAL IMAGING ONCOLOGY Responding by growing the renal footprint across South Africa INCREASE IN NUMBER OF ACHIEVED THROUGH… RENAL UNITS AND BEDS ACROSS SOUTH AFRICA AND Acquisition of new facilities, rapidly growing our presence NAMIBIA Additional 5 renal Additional renal units operational fr
Slide 30: Opportunity identified in radiology and nuclear medicine
ACUTE RENAL IMAGING ONCOLOGY Opportunity identified in radiology and nuclear medicine Low utilisation South Africa reflects extremely low imaging penetration when compared to 32 Well-positioned European countries supporting the growth potential – fitting in at 6th lowest in comparison for CT and MRI
Slide 31: Continue investment into diagnostic imaging services
ACUTE RENAL IMAGING ONCOLOGY Continue investment into diagnostic imaging services in South Africa Well-developed private radiology market with Existing imaging growing demand... 11 locations (incl Gaborone) Double Imaging R700m Digit >6% +4 facilities in Growth progress and planned Invested to date
Slide 32: Growing ahead of anticipated demand for nuclear medicine
ACUTE RENAL IMAGING ONCOLOGY Growing ahead of anticipated demand for nuclear medicine services in South Africa Growing nuclear medicine Achieved through… services in key geographies The nuclear medicine footprint is expanding: Existing PET-CT and SPECT-CT 3 facilities Pretoria Johannesburg Additiona
Slide 33: Delivering improved patient outcomes through PET-CT
ACUTE RENAL IMAGING ONCOLOGY Delivering improved patient outcomes through PET-CT PET-CT imaging This enables Studies demonstrate that this provides.. clinicians to.. impacts patient outcomes... Use of PET-CT is associated Increased Improve Improve with improved event-free sensitivity staging surviva
Slide 34: Delivering improved patient outcomes through PET-CT
ACUTE RENAL IMAGING ONCOLOGY Delivering improved patient outcomes through PET-CT An increase of >60% in PET-CT scans are a Accurately pinpoints new cancer cases in diagnostic tool used Radioactive tracer cancer and it's defining forecasted in south to detect cancer in the injected or ingested factor
Slide 35: Opportunity to be a market leader in nuclear medicine
ACUTE RENAL IMAGING ONCOLOGY Opportunity to be a market leader in the growth of the nuclear medicine in South Africa … An untapped opportunity in nuclear medicine … The state of play in South Africa … • Nuclear medicine, particularly PET-CT, remains a grossly underutilised modality in SA R1bn SA pri
Slide 36: Market opportunity is significant due to outdated guidelines
ACUTE RENAL IMAGING ONCOLOGY Market opportunity is significant due to outdated guidelines ADDRESSABLE R1bn p.a. (estimated) opportunity available through aligning Local Nuclear Medicine Guidelines to global best OPPORTUNITY practice, therefore providing an additional c. 30,000 – 40, 000 PET-CT scans
Slide 37: UK growth: a case for change
ACUTE RENAL IMAGING ONCOLOGY UK growth: a case for change The UK has been on a journey to ‘close the gap’ with Europe on PET-CT availability and adoption There are several factors that have contributed to the significant growth of PET-CT in the UK, namely: • Government support; South Africa • A cros
Slide 38: Leveraging opportunities to enable growth of nuclear medicine
A GCRUOTWE R D ER NI VAEL OI M PTA IGMI INSGE ONCOLOGY Leveraging opportunities to enable growth of nuclear medicine in South Africa Opportunities to drive wider How opportunities are being addressed nuclear medicine adoption* Unreliable and expensive Building 2 cyclotrons in a JV to provide reliabl
Slide 39: Increasing demand for oncology services in South Africa
ACUTE RENAL IMAGING ONCOLOGY Increasing demand for oncology services in South Africa Greater demand for oncological services in South Africa.... +12% 40% Average annual growth rate in Of severe illness benefit costs per life of cancer patients payouts by Discovery Life are over the last five years1
Slide 40: Growing the oncology footprint in South Africa
ACUTE RENAL IMAGING ONCOLOGY Growing the oncology footprint in South Africa Life Healthcare is expanding Achieved through… upon existing oncology networks Existing footprint Gaborone 5 • 5 existing radiotherapy units Pretoria Johannesburg Scaling our existing footprint • Oncology Units: through acqu
Slide 41: Positioning as lead provider of comprehensive oncology services
ACUTE RENAL IMAGING ONCOLOGY Positioning Life Healthcare as the lead provider of comprehensive oncology services in South Africa By: Coupled with: Resulting in: Ensuring physical presence and geographic Patient- centered coverage by means approach with care Growth in the of radiotherapy coordination
Slide 42: Increasing the number of units aligned to where services are required
ACUTE RENAL IMAGING ONCOLOGY Increasing the number of units aligned to where services are required I N C R E AS I N G C APA C I T Y ACHIEVED THROUGH… Brownfield expansion at existing facilities where demand is high In Progress: In Planning: Pretoria +180 105 Acute beds (ICU /GW) +156 106 Acute beds
Slide 43: Grow: Questions
SECTION 1: GROW GROW QUESTIONS
Slide 44: Section 2: Drive
SECTION 2: DRIVE DRIVE ACUTE Slides 45-64 HOW? GP channel A&E unit channel Maximise facilities utilisation and Dr recruitment and retention deliver Disease channel sustainable topline growth Funder and network Value-based care and ICPs
Slide 45: Drive overview
ACUTE RENAL IMAGING ONCOLOGY Drive overview • G P R E F E R R A L S U P P O R T F U N D A M E N TA L T O S P E C I A L I S T NETWORK G P C H AN N E L • E S TA B L I S H I N G L I N K S V I A R E L AT I O N S H I P B U I L D I N G A N D C P D S AT H O S P I TA L L E V E L • Q U A L I T Y O F S TA F F
Slide 46: Well-functioning A&E units are assets to our hospitals
ACUTE RENAL IMAGING ONCOLOGY Well-functioning A&E units are assets to our hospitals Marketing and awareness with doctors to highlight investments made to enhance facilities: State- of-the- A&Es A&Es contribute 25% of hospital art tech admissions General ICUs Ward Upgrades A&E upgrades and expansion:
Slide 47: Attract and retain doctors in key disciplines (1 of 2)
ACUTE RENAL IMAGING ONCOLOGY Attract and retain doctors in key disciplines (1 of 2) U n d e r f u n d i ng o f Fo c u s o n s p e c i ali sts s p e c ialist t rain i n g i n B e n ef i t s an d s u b - sp e ci alists S o u t h Af rica Tr a i n i n g o v e r FY2025 – FY2033 Over the next 8 years we A
Slide 48: Attract and retain doctors in key disciplines (2 of 2)
ACUTE RENAL IMAGING ONCOLOGY Attract and retain doctors in key disciplines (2 of 2) Short term recruitment to plug the gaps Retention Practice set up Funder network Long term recruitment for future proofing support deals Hospital ecosystem – quality staff, Dr shareholding Life Healthcare aims to hav
Slide 49: Drive overview
ACUTE RENAL IMAGING ONCOLOGY Drive overview • G P R E F E R R A L S U P P O R T F U N D A M E N TA L T O S P E C I A L I S T NETWORK G P C H AN N E L • E S TA B L I S H I N G L I N K S V I A R E L AT I O N S H I P B U I L D I N G A N D C P D S AT H O S P I TA L L E V E L • Q U A L I T Y O F S TA F F
Slide 50: Value proposition for negotiating contracts with funders
Our compelling value proposition for negotiating contracts with funders is fundamental to our future success Nurture relationships and secure contracts with the major medical schemes to negotiate favourable tariffs and maximise utilisation of Life Healthcare facilities. Maintain Leverage value- Alig
Slide 51: Major player in funder network deals
Life Healthcare has always been a major player in funder network deals due to our market leading efficiency and quality outcomes Beneficiaries Network PPD's 3 5 % ( ~ 3 m ) of s c h e m e b e n e f i c i a r i e s w e r e p a r t of a n e t w or k a r r a n g e m e n t i n 2 0 2 2 L i f e H e a l t
Slide 52: Value-based care: The next step in our journey
Value-based care: The next step in our journey Funder relations Value-based care (VBC) integrates Outcomes our expertise in funder relations, Product innovation product innovation, data analytics and Data analytics Costs technology to lower costs and improve Technology patient outcomes 52
Slide 53: Our VBC strategy is a strong response to market conditions
Our VBC strategy is a strong response to the current market conditions Our value-based care strategy will… Differentiate us Enable Life Healthcare to Help us grow market share Help us improve from become the provider of in a flat market outside of returns competitors choice for funders (DSP) pure di
Slide 54: The VBC value creation lifecycle underpins our strategy
The VBC value creation lifecycle underpins our strategy Value-based carere value creation lifecycle Key initiatives across admission, episode & patient dimensions Increase absolute 6 • Improve length of stay, level of admissions 1 Deliver patient-centred, acuity and cost of sales, standardised evide
Slide 55: Value-based care products transform delivery and create value
CARE DELIVERY VALUE CAPTURE MARKET SHARE Value-based care products transform delivery and create value From To By developing Current State of Facilitating Enhanced system value state V a l u e - b a s e d c a re p ro d u c t s u s i n g D e l i v e ry o f C a re a c t i v e l y de l i v e ri n g c o
Slide 56: VBC is underpinned by value contracting
CARE DELIVERY V A L U E C A P T U R E MARKET SHARE VBC is underpinned by value contracting We have first mover advantage ARMS AND GLOBAL FEES VALUE CONTRACTING W e w e r e f i r s t m ov e r s i n i m p l e m e n t i n g AR M S a n d G l ob a l f e e s W e a r e n ow a l s o f i r s t move r i n va
Slide 57: Value-based contracting reduces total cost of care
CARE DELIVERY V A L U E C A P T U R E MARKET SHARE Value-based contracting gives Life Healthcare the opportunity to reduce the total cost of care and grow profit 1 2 C O M M E N TA RY 3 Total Cost reduced total cost of care Shared Value Profit Shared Value 1 Initial product cost based on cost neutra
Slide 58: Effective implementation leads to market share and occupancy gains
CARE DELIVERY V A L U E C A P T U R E MARKET SHARE Effective implementation leads to market share and occupancy gains Current Market share growth New Market share ILLUSTRATIVE #S Patient #s 1000 +300 1300 VA LU E S H I F T F RO M THE ICP Normal admissions • By improving patient compliance (no ICP) 3
Slide 59: Technology Capabilities implemented to deliver VBC
CARE DELIVERY V A L U E C A P T U R E MARKET SHARE Technology Capabilities implemented to deliver VBC C O R E C A PA B I L I T I E S COMPLEXITY O u r t e c h n ol og i e s w or k i n a n i n t e r c on n e c t e d w a y t o e n a b l e ou r c or e c a p a b i l i t i e s T h e y a l s o h a ve va r
Slide 60: VBC renal programme delivering value and market share
Our VBC renal programme (Renal Integrated Care Product) is delivering significant value, growing market share and occupancy Becoming the preferred provider will boost patient 6 1 Through coordinated care management and appropriate patient-centric care with quality clinical referrals, increasing occu
Slide 61: The Renal ICP has scaled to 30 sites
The Renal ICP has scaled to 30 sites and delivered significant benefits to lower the overall cost of care IMPROVED CLINICAL QUALITY AND REDUCED PATIENT ENHANCED PATIENT EXPERIENCE ADMISSIONS 97% 17% 85% Patients reported a seamless transition Patient compliance to Reduction in patient hospital Patie
Slide 62: On track to be the renal designated service provider
Life Healthcare is on track to be the renal designated service provider The renal ICP will be further rolled-out across recently acquired units, scaling its impact further; Rolled out renal ICP to all hospital affiliated renal +30 units Currently rolling out the renal ICP to 11 Life Renal +11 Dialys
Slide 63: Capabilities to launch additional VBC products
Life Healthcare has the capabilities to launch additional VBC products 2024+ 2021 2022 - 2024 B U I L D F O U N DAT I O N A L L AU N C H A N D S C A L E L AU N C H A N D S C A L E C A PA B I LI T IE S RENAL ICP 2 A D D I T I O N A L I C Ps • Repositioned funder relationships • Scaled renal ICP to 30
Slide 64: Drive overview
Drive overview • G P R E F E R R A L S U P P O R T F U N D A M E N TA L T O S P E C I A L I S T NETWORK G P C H AN N E L • E S TA B L I S H I N G L I N K S V I A R E L AT I O N S H I P B U I L D I N G A N D C P D S AT H O S P I TA L L E V E L • Q U A L I T Y O F S TA F F / D R S A& E U N I T • Q U A
Slide 65: Drive: Questions
SECTION 2: DRIVE DRIVE QUESTIONS
Slide 66: Section 3: Optimisation
SECTION 3: OPTIMISATION OPTIMISE OPTIMISE Slides 67-69 HOW? Strategically optimise asset utilisation Ensure an optimised, Streamline business operations efficient portfolio of assets and streamlined Capital allocation business operations
Slide 67: Optimisation efforts to improve efficiencies and deliver sustainable margins
Optimisation efforts to improve efficiencies and deliver sustainable margins 1 Improve asset utilisation to improve operational leverage and result in improve returns Financial Breakdown % of Revenue 2 Revenue 100% Cost of sales 32% • PROCUREMENT Drugs and Surgicals 28% • UTILISATION REVIEW Other 4%
Slide 68: Key success metrics to monitor progress
Key success metrics to monitor progress in achieving the strategy Imaging & Nuclear Acute Acute Rehab Mental Health Renal Dialysis Medicine Oncology GROW Beds Stations Number of Imaging Patient volumes and Nuclear sites Number of new REVENUE machines Occupancy rate DRIVE Admissions and revenue from
Slide 69: Capital allocation and investing for growth
Capital allocation and investing for growth Life Healthcare Capital Allocation 1 2 3 4 RETURN TO MAINTENANCE OF CAPEX REPAYMENT OF DEBT GROWTH OF CAPEX SHAREHOLDERS Enable organic / inorganic growth Distribute excess distributable Sustain existing business Service external debt and innovative opport
Slide 70: Optimise: Questions
SECTION 3: OPTIMISATION OPTIMISE QUESTIONS
Slide 71: Section 4: Conclusion
SECTION 4: CONCLUSION CONCLUSION Life Healthcare have successfully adapted the strategy to ensure that it is best- positioned for increasing RMR i.e. Returns, Market share and Revenue
Slide 72: Grow, Drive, Optimise
ACUTE RENAL IMAGING ONCOLOGY Grow, Drive, Optimise Life Healthcare have successfully adapted the strategy to ensure that it is best-positioned for increasing RMR i.e. Returns, Market share and Revenue 72
Slide 73: Expanding our footprint over the next 5 years
2019 2024 2029 est. ACUTE BEDS 8,225 8,145 8,496 – 8,700 AR/MH BEDS 911 894 1,019 – 1,250 RD STATIONS 329 1,012 1,065 – 1,200 ONCOLOGY UNITS 5 5 8 - 10 IMAGING UNITS - 7 12 - 18 PET-CT UNITS - 3 8 - 10 CYCLOTRONS - - 2-4 EXPANDING OUR FOOTPRINT OVER THE NEXT 5 YEARS WILL RESULT IN A MEANINGFUL EXPAN
Slide 74: Optimise to 2029
OPTIMISE TO 2029 2019 2024 2029 est. OCCUPANCY % 69.7% 69.0% >70% VBC PRODUCTS - 1 >5 EBITDA MARGIN 23.8% 15.5% > 17% Net/debt to EBITDA 1.96x 0.45x 0.45x – 1.5x ROCE 14.5% 19.8% 20-22% OUR 5 YEAR PLAN WILL ENSURE THAT WE MAXIMISE FACILITIES UTILISATION AND DELIVER SUSTAINABLE TOPLINE GROWTH WHILST
Slide 75: Grow, Drive, Optimise: FY2025 Progress
Grow, Drive, Optimise: FY2025 Progress 219 beds: • 79 beds in FY2025 • Commence build of 140 bed hospital GROW Imaging transactions underway New PET-CT sites DRIVE Occupancies to 70% through PPD growth of 1.0% - 1.5% Focus on operational efficiencies OPTIMISE Embed FMC renal operations Expand roll-o
Slide 76: Good growth: 2029 revenue by segment
Good growth: 2029 39 000 37 000 Revenue by segment CAGR CAGR 35 000 33 000 31 000 29 000 13.5 – 17.0% 27 000 25 000 23 000 21 000 6.3 – 7.0% 19 000 17 000 15 000 2019 2022 2023 2024 2029 Acute Comp Serv HCS Life Healthcare has 3 business lines – Acute, Complementary Services, and HCS Acute Core part
Slide 77: Conclusion: Questions
SECTION 4: CONCLUSION CONCLUSION QUESTIONS
Slide 78: Section 5: Life Molecular Imaging
SECTION 5: LIFE MOLECULAR IMAGING LIFE MOLECULAR IMAGING LMI TRANSACTION OVERVIEW
Slide 79: Transaction summary
Transaction summary 1 ▪ The disposal by Life Healthcare, through its wholly owned subsidiary Life Medical Group Limited (LMGL) of 100% of Life Molecular The transaction Imaging (LMI) to Lantheus Holdings Inc. (Lantheus) 2 Overview of the ▪ Lantheus is a leading radiopharmaceutical-focused company wi
Slide 80: Transaction summary
Transaction summary In addition to the Purchase Consideration, Life Healthcare retains the right to Africa and net economic benefits to RM2 Purchase Consideration (US$m) RM2 and Africa licensing 50 125 50 225 125 In addition, as part of the 225 750 transaction, Life Healthcare will retain: 350 ✓Righ
Slide 81: Net proceeds to Life Healthcare
Net proceeds to Life Healthcare Life Healthcare intends to return the net proceeds of the upfront payment to shareholders within 12 months of closing US$m Upfront Payment1 Potential Earnouts2 (Within 12 months of closing) (Between 2026 and 2034) Upfront payment 350 Est. earnout 1 (NeuraCeq USA sales
Slide 82: Life Molecular Imaging: Questions
SECTION 5: LIFE MOLECULAR IMAGING LIFE MOLECULAR IMAGING QUESTIONS
Slide 83: Appendix
Contents Appendix
Slide 84: Nuclear Medicine: Global Guidelines authority sources
Nuclear Medicine: Global Guidelines authority sources (slide 37) Cancer Type South Africa UK European US Australia CANSA European Commission NCCN NICE Breast CMS ECDC SNMMI ANZSNM RCR SAMJ ACR NCCN CMS NHS Colon ESMO SNMMI ANZSNM SAMJ RCR ACR NCCN SAMJ NICE Prostate ESMO SNMMI ANZSNM SA Prostate Can
Life Healthcare Group Holdings — Investor Day (February 2025) on 6ix